Phosphate—a poison for humans?

Kidney International

Volumn 90, Issue 4, 2016, Pages 753-763

  Komaba, Hirotaka ^a,b   Fukagawa, Masafumi ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKAI UNIVERSITY   (Japan)

Author keywords

chronic kidney disease; fibroblastic growth factor 23; parathyroid hormone; phosphate

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE; POISON; FIBROBLAST GROWTH FACTOR; MINERAL; PHOSPHATE INTAKE; VITAMIN D;

AGING; BONE DISEASE; CARDIOVASCULAR SYSTEM; CHRONIC KIDNEY FAILURE; CLINICAL OUTCOME; CLINICAL PRACTICE; DIET THERAPY; DISEASE ASSOCIATION; HUMAN; KIDNEY; MINERAL METABOLISM; PARATHYROID HORMONE BLOOD LEVEL; PATHOGENESIS; PHOSPHATE BLOOD LEVEL; PHOSPHATE INTAKE; PHOSPHATE METABOLISM; PROTEIN BLOOD LEVEL; REVIEW; ANIMAL; BLOOD; COMPLICATION; HEMODIALYSIS; HOMEOSTASIS; HYPERPHOSPHATEMIA; METABOLISM; PHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; SECONDARY HYPERPARATHYROIDISM; URINARY EXCRETION;

ANIMALS; BONE DISEASES; FIBROBLAST GROWTH FACTORS; HOMEOSTASIS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPERPHOSPHATEMIA; KIDNEY; MINERALS; PARATHYROID HORMONE; PHOSPHATES; PHOSPHORUS, DIETARY; RENAL DIALYSIS; RENAL ELIMINATION; RENAL INSUFFICIENCY, CHRONIC; VITAMIN D;

EID: 85015431783     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2016.03.039     Document Type: Review

References (146)

1. 1 Krafft, F., Phosphorus. From elemental light to chemical element. Angew Chem Int Ed Engl 8 (1969), 660–671.
2. 2 Razzaque, M.S., Phosphate toxicity: new insights into an old problem. Clin Sci (Lond) 120 (2011), 91–97.
3. 3 Kuro-o, M., A phosphate-centric paradigm for pathophysiology and therapy of chronic kidney disease. Kidney Int Suppl 3 (2013), 420–426.
4. 4 Komaba, H., Fukagawa, M., FGF23-parathyroid interaction: implications in chronic kidney disease. Kidney Int 77 (2010), 292–298.
5. 5 Kestenbaum, B., Sampson, J.N., Rudser, K.D., et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16 (2005), 520–528.
6. 6 Eddington, H., Hoefield, R., Sinha, S., et al. Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol 5 (2010), 2251–2257.
7. 7 Block, G.A., Klassen, P.S., Lazarus, J.M., et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15 (2004), 2208–2218.
8. 8 Tentori, F., Blayney, M.J., Albert, J.M., et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 52 (2008), 519–530.
9. 9 Taniguchi, M., Fukagawa, M., Fujii, N., et al. Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients. Ther Apher Dial 17 (2013), 221–228.
10. 10 Tonelli, M., Sacks, F., Pfeffer, M., et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 112 (2005), 2627–2633.
11. 11 Dhingra, R., Sullivan, L.M., Fox, C.S., et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 167 (2007), 879–885.
12. 12 Foley, R.N., Collins, A.J., Herzog, C.A., et al. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol 20 (2009), 397–404.
13. 13 Uribarri, J., Phosphorus additives in food and their effect in dialysis patients. Clin J Am Soc Nephrol 4 (2009), 1290–1292.
14. 14 Kalantar-Zadeh, K., Gutekunst, L., Mehrotra, R., et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol 5 (2010), 519–530.
15. 15 Sabbagh, Y., O'Brien, S.P., Song, W., et al. Intestinal npt2b plays a major role in phosphate absorption and homeostasis. J Am Soc Nephrol 20 (2009), 2348–2358.
16. 3. Am J Physiol Cell Physiol 282 (2002), C487–C493.
17. 17 Segawa, H., Kaneko, I., Yamanaka, S., et al. Intestinal Na-P(i) cotransporter adaptation to dietary P(i) content in vitamin D receptor null mice. Am J Physiol Renal Physiol 287 (2004), F39–F47.
18. 18 Moe, S.M., Zidehsarai, M.P., Chambers, M.A., et al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol 6 (2011), 257–264.
19. 19 Segawa, H., Onitsuka, A., Furutani, J., et al. Npt2a and Npt2c in mice play distinct and synergistic roles in inorganic phosphate metabolism and skeletal development. Am J Physiol Renal Physiol 297 (2009), F671–F678.
20. 20 Déliot, N., Hernando, N., Horst-Liu, Z., et al. Parathyroid hormone treatment induces dissociation of type IIa Na+-P(i) cotransporter-Na+/H+ exchanger regulatory factor-1 complexes. Am J Physiol Cell Physiol 289 (2005), C159–C167.
21. 21 Weinman, E.J., Biswas, R.S., Peng, G., et al. Parathyroid hormone inhibits renal phosphate transport by phosphorylation of serine 77 of sodium-hydrogen exchanger regulatory factor-1. J Clin Invest 117 (2007), 3412–3420.
22. 22 Shimada, T., Hasegawa, H., Yamazaki, Y., et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19 (2004), 429–435.
23. 23 Shimada, T., Kakitani, M., Yamazaki, Y., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113 (2004), 561–568.
24. 24 Urakawa, I., Yamazaki, Y., Shimada, T., et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444 (2006), 770–774.
25. 25 Kurosu, H., Ogawa, Y., Miyoshi, M., et al. Regulation of fibroblast growth factor-23 signaling by Klotho. J Biol Chem 281 (2006), 6120–6123.
26. 26 Kuro-o, M., Matsumura, Y., Aizawa, H., et al. Mutation of the mouse Klotho gene leads to a syndrome resembling ageing. Nature 390 (1997), 45–51.
27. 27 Farrow, E.G., Davis, S.I., Summers, L.J., et al. Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J Am Soc Nephrol 20 (2009), 955–960.
28. 28 Olauson, H., Lindberg, K., Amin, R., et al. Targeted deletion of Klotho in kidney distal tubule disrupts mineral metabolism. J Am Soc Nephrol 23 (2012), 1641–1651.
29. 29 Lindberg, K., Amin, R., Moe, O.W., et al. The kidney is the principal organ mediating klotho effects. J Am Soc Nephrol 25 (2014), 2169–2175.
30. 30 Andrukhova, O., Zeitz, U., Goetz, R., et al. FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2-SGK1 signaling pathway. Bone 51 (2012), 621–628.
31. 31 Hu, M.C., Shiizaki, K., Kuro-o, M., et al. Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol 75 (2013), 503–533.
32. 32 Hu, M.C., Shi, M., Zhang, J., Pastor, J., et al. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J 24 (2010), 3438–3450.
33. 33 Slatopolsky, E., Finch, J., Denda, M., et al. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 97 (1996), 2534–2540.
34. 34 Almaden, Y., Canalejo, A., Hernandez, A., et al. Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J Bone Miner Res 11 (1996), 970–976.
35. 35 Ferrari, S.L., Bonjour, J.P., Rizzoli, R., Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90 (2005), 1519–1524.
36. 36 Burnett, S.M., Gunawardene, S.C., Bringhurst, F.R., et al. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 21 (2006), 1187–1196.
37. 37 Antoniucci, D.M., Yamashita, T., Portale, A.A., Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 91 (2006), 3144–3149.
38. 38 Ito, N., Fukumoto, S., Takeuchi, Y., et al. Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J Bone Miner Metab 25 (2007), 419–422.
39. 39 Liu, S., Tang, W., Zhou, J., et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17 (2006), 1305–1315.
40. 40 Hori, M., Kinoshita, Y., Taguchi, M., et al. Phosphate enhances Fgf23 expression through reactive oxygen species in UMR-106 cells. J Bone Miner Metab 34 (2016), 132–139.
41. 41 Berndt, T., Thomas, L.F., Craig, T.A., et al. Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption. Proc Natl Acad Sci U S A 104 (2007), 11085–11090.
42. 42 Shigematsu, T., Kazama, J.J., Yamashita, T., et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 44 (2004), 250–256.
43. 43 Gutierrez, O., Isakova, T., Rhee, E., et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16 (2005), 2205–2215.
44. 44 Isakova, T., Wahl, P., Vargas, G.S., et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79 (2011), 1370–1378.
45. 45 Mace, M.L., Gravesen, E., Hofman-Bang, J., et al. Key role of the kidney in the regulation of fibroblast growth factor 23. Kidney Int 88 (2015), 1304–1313.
46. 46 Taal, M.W., Thurston, V., McIntyre, N.J., et al. The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease. Kidney Int 86 (2014), 407–413.
47. 47 de Seigneux, S., Courbebaisse, M., Rutkowski, J.M., et al. Proteinuria increases plasma phosphate by altering its tubular handling. J Am Soc Nephrol 26 (2015), 1608–1618.
48. 48 Schafer, C., Heiss, A., Schwarz, A., et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 112 (2003), 357–366.
49. 49 Price, P.A., Lim, J.E., The inhibition of calcium phosphate precipitation by fetuin is accompanied by the formation of a fetuin-mineral complex. J Biol Chem 278 (2003), 22144–22152.
50. 50 Cai, M.M., Smith, E.R., Holt, S.G., The role of fetuin-A in mineral trafficking and deposition. Bonekey Rep, 4, 2015, 672.
51. 51 Herrmann, M., Schäfer, C., Heiss, A., et al. Clearance of fetuin-A-containing calciprotein particles is mediated by scavenger receptor-A. Circ Res 111 (2012), 575–584.
52. 52 Streja, E., Lau, W.L., Goldstein, L., et al. Hyperphosphatemia is a combined function of high serum PTH and high dietary protein intake in dialysis patients. Kidney Int Suppl 3 (2013), 462–468.
53. 53 Koizumi, M., Komaba, H., Nakanishi, S., et al. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 27 (2012), 784–790.
54. 54 Moe, S.M., Chertow, G.M., Parfrey, P.S., et al. Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Circulation 132 (2015), 27–39.
55. 55 Sato, T., Tominaga, Y., Ueki, T., et al. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis 44 (2004), 481–487.
56. 56 Takahashi, H., Komaba, H., Takahashi, Y., et al. Impact of parathyroidectomy on serum FGF23 and soluble Klotho in hemodialysis patients with severe secondary hyperparathyroidism. J Clin Endocrinol Metab 99 (2014), E652–E658.
57. 57 Kestenbaum, B., Andress, D.L., Schwartz, S.M., et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int 66 (2004), 2010–2016.
58. 58 Komaba, H., Taniguchi, M., Wada, A., et al. Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int 88 (2015), 350–359.
59. 59 EVOLVE Trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367 (2012), 2482–2494.
60. 60 Martin, K.J., Pickthorn, K., Huang, S., et al. AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients. Kidney Int 85 (2014), 191–197.
61. 61 Bricker, N.S., On the pathogenesis of the uremic state. An exposition of the ‘trade-off hypothesis’. N Engl J Med 286 (1972), 1093–1099.
62. 62 Hasegawa, H., Nagano, N., Urakawa, I., et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 78 (2010), 975–980.
63. 63 Ben-Dov, I.Z., Galitzer, H., Lavi-Moshayoff, V., et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117 (2007), 4003–4008.
64. 64 Komaba, H., Goto, S., Fujii, H., et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 77 (2010), 232–238.
65. 65 Galitzer, H., Ben-Dov, I.Z., Silver, J., et al. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 77 (2010), 211–218.
66. 66 Portale, A.A., Booth, B.E., Halloran, B.P., et al. Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 73 (1984), 1580–1589.
67. 67 Stubbs, J.R., Liu, S., Tang, W., et al. Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol 18 (2007), 2116–2124.
68. 68 Moallem, E., Kilav, R., Silver, J., et al. RNA-Protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J Biol Chem 273 (1998), 5253–5259.
69. 69 Cozzolino, M., Lu, Y., Sato, T.J., et al. A critical role for enhanced TGF-alpha and EGFR expression in the initiation of parathyroid hyperplasia in experimental kidney disease. Am J Physiol Renal Physiol 289 (2005), F1096–F1102.
70. 70 Topaz, O., Shurman, D.L., Bergman, R., et al. Mutations in GALNT3 encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 36 (2004), 579–581.
71. 71 Benet-Pages, A., Orlik, P., Strom, T.M., et al. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 14 (2005), 385–390.
72. 72 Larsson, T., Yu, X., Davis, S.I., et al. A novel recessive mutation in fibroblast growth factor-23 (FGF23) causes familial tumoral calcinosis. J Clin Endocrinol Metab 90 (2005), 2424–2427.
73. 73 Araya, K., Fukumoto, S., Backenroth, R., et al. A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab 90 (2005), 5523–5527.
74. 74 Ichikawa, S., Imel, E.A., Kreiter, M.L., et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 117 (2007), 2684–2691.
75. 75 Kato, K., Jeanneau, C., Tarp, M.A., et al. Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem 281 (2006), 18370–18377.
76. 76 Frishberg, Y., Ito, N., Rinat, C., et al. Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J Bone Miner Res 22 (2007), 235–242.
77. 77 Jono, S., McKee, M.D., Murry, C.E., et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87 (2000), E10–E17.
78. 78 Chen, N.X., O'Neill, K.D., Duan, D., et al. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 62 (2002), 1724–1731.
79. 79 Moe, S.M., O'Neill, K.D., Duan, D., et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 61 (2002), 638–647.
80. 80 Lin, M.E., Chen, T., Leaf, E.M., et al. Runx2 expression in smooth muscle cells is required for arterial medial calcification in mice. Am J Pathol 185 (2015), 1958–1969.
81. 81 Reynolds, J.L., Joannides, A.J., Skepper, J.N., et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 15 (2004), 2857–2867.
82. 82 Shroff, R.C., McNair, R., Skepper, J.N., et al. Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. J Am Soc Nephrol 21 (2010), 103–112.
83. 83 Yamada, S., Tokumoto, M., Tatsumoto, N., et al. Phosphate overload directly induces systemic inflammation and malnutrition as well as vascular calcification in uremia. Am J Physiol Renal Physiol 306 (2014), F1418–F1428.
84. 84 Li, X., Yang, H.Y., Giachelli, C.M., Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 98 (2006), 905–912.
85. 85 Sage, A.P., Lu, J., Tintut, Y., et al. Hyperphosphatemia-induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro. Kidney Int 79 (2011), 414–422.
86. 86 Ewence, A.E., Bootman, M., Roderick, H.L., et al. Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization. Circ Res 103 (2008), e28–e34.
87. 87 Hamano, T., Matsui, I., Mikami, S., et al. Fetuin-mineral complex reflects extraosseous calcification stress in CKD. J Am Soc Nephrol 21 (2010), 1998–2007.
88. 88 Smith, E.R., Ford, M.L., Tomlinson, L.A., et al. Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD. Nephrol Dial Transplant 27 (2012), 1957–1966.
89. 89 Lim, K., Lu, T.S., Molostvov, G., et al. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 125 (2012), 2243–2255.
90. 90 Scialla, J.J., Lau, W.L., Reilly, M.P., et al. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int 83 (2013), 1159–1168.
91. 91 Jimbo, R., Kawakami-Mori, F., Mu, S., et al. Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency. Kidney Int 85 (2014), 1103–1111.
92. 92 Di Marco, G.S., Hausberg, M., Hillebrand, U., et al. Increased inorganic phosphate induces human endothelial cell apoptosis in vitro. Am J Physiol Renal Physiol 294 (2008), F1381–F1387.
93. 93 Peng, A., Wu, T., Zeng, C., et al. Adverse effects of simulated hyper- and hypo-phosphatemia on endothelial cell function and viability. PLoS One, 6, 2011, e23268.
94. 94 Shuto, E., Taketani, Y., Tanaka, R., et al. Dietary phosphorus acutely impairs endothelial function. J Am Soc Nephrol 20 (2009), 1504–1512.
95. 95 Yilmaz, M.I., Sonmez, A., Saglam, M., et al. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. Am J Kidney Dis 59 (2012), 177–185.
96. 96 Ayus, J.C., Mizani, M.R., Achinger, S.G., et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol 16 (2005), 2778–2788.
97. 97 Chue, C.D., Edwards, N.C., Moody, W.E., et al. Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: a cardiac magnetic resonance study. Heart 98 (2012), 219–224.
98. 98 Amann, K., Tornig, J., Kugel, B., et al. Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int 63 (2003), 1296–1301.
99. 99 Neves, K.R., Graciolli, F.G., dos Reis, L.M., et al. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. Kidney Int 66 (2004), 2237–2244.
100. 100 Gutiérrez, O.M., Januzzi, J.L., Isakova, T., et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119 (2009), 2545–2552.
101. 101 Faul, C., Amaral, A.P., Oskouei, B., et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 121 (2011), 4393–4408.
102. 102 Grabner, A., Amaral, A.P., Schramm, K., et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab 22 (2015), 1020–1032.
103. 103 Andrukhova, O., Slavic, S., Smorodchenko, A., et al. FGF23 regulates renal sodium handling and blood pressure. EMBO Mol Med 6 (2014), 744–759.
104. 104 Schlüter, K.D., Piper, H.M., Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res 37 (1998), 34–41.
105. 105 Markowitz, G.S., Perazella, M.A., Acute phosphate nephropathy. Kidney Int 76 (2009), 1027–1034.
106. 106 Haut, L.L., Alfrey, A.C., Guggenheim, S., et al. Renal toxicity of phosphate in rats. Kidney Int 17 (1980), 722–731.
107. 107 Kusano, K., Segawa, H., Ohnishi, R., et al. Role of low protein and low phosphorus diet in the progression of chronic kidney disease in uremic rats. J Nutr Sci Vitaminol (Tokyo) 54 (2008), 237–243.
108. 108 Koizumi, T., Murakami, K., Nakayama, H., et al. Role of dietary phosphorus in the progression of renal failure. Biochem Biophys Res Commun 295 (2002), 917–921.
109. 109 Barsotti, G., Giannoni, A., Morelli, E., et al. The decline of renal function slowed by very low phosphorus intake in chronic renal patients following a low nitrogen diet. Clin Nephrol 21 (1984), 54–59.
110. 110 Schwarz, S., Trivedi, B.K., Kalantar-Zadeh, K., et al. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol 1 (2006), 825–831.
111. 111 Fliser, D., Kollerits, B., Neyer, U., et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 18 (2007), 2600–2608.
112. 112 Isakova, T., Xie, H., Yang, W., et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305 (2011), 2432–2439.
113. 113 Nakano, C., Hamano, T., Fujii, N., et al. Combined use of vitamin D status and FGF23 for risk stratification of renal outcome. Clin J Am Soc Nephrol 7 (2012), 810–819.
114. 114 Rebholz, C.M., Grams, M.E., Coresh, J., et al. Serum fibroblast growth factor-23 is associated with incident kidney disease. J Am Soc Nephrol 26 (2015), 192–200.
115. 115 Wolf, M., The biomarker niche for fibroblast growth factor 23 testing in CKD. J Am Soc Nephrol 26 (2015), 7–9.
116. 116 Katsumata, K., Kusano, K., Hirata, M., et al. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney Int 64 (2003), 441–450.
117. 117 Ferreira, A., Frazão, J.M., Monier-Faugere, M.C., et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 19 (2008), 405–412.
118. 118 Malluche, H.H., Siami, G.A., Swanepoel, C., et al. Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol 70 (2008), 284–295.
119. 119 Wang, H., Yoshiko, Y., Yamamoto, R., et al. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res 23 (2008), 939–948.
120. 3 and Klotho-independent manner. J Bone Miner Res 31 (2016), 129–142.
121. 121 Mirza, M.A., Karlsson, M.K., Mellström, D., et al. Serum fibroblast growth factor-23 (FGF-23) and fracture risk in elderly men. J Bone Miner Res 26 (2011), 857–864.
122. 122 Isakova, T., Cai, X., Lee, J., et al. Associations of FGF23 with change in bone mineral density and fracture risk in older individuals. J Bone Miner Res 31 (2016), 742–748.
123. 123 Morishita, K., Shirai, A., Kubota, M., et al. The progression of aging in klotho mutant mice can be modified by dietary phosphorus and zinc. J Nutr 131 (2001), 3182–3188.
124. 124 Ohnishi, M., Nakatani, T., Lanske, B., et al. In vivo genetic evidence for suppressing vascular and soft-tissue calcification through the reduction of serum phosphate levels, even in the presence of high serum calcium and 1,25-dihydroxyvitamin d levels. Circ Cardiovasc Genet 2 (2009), 583–590.
125. 125 Sitara, D., Kim, S., Razzaque, M.S., et al. Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet, 4, 2008, e1000154.
126. 126 Ohnishi, M., Razzaque, M.S., Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging. FASEB J 24 (2010), 3562–3571.
127. 127 Bergwitz, C., Dietary phosphate modifies lifespan in. Drosophila. Nephrol Dial Transplant 27 (2012), 3399–3406.
128. 128 Nguyen, T.T., Quan, X., Hwang, K.H., et al. Mitochondrial oxidative stress mediates high-phosphate-induced secretory defects and apoptosis in insulin-secreting cells. Am J Physiol Endocrinol Metab 308 (2015), E933–E941.
129. 129 Jin, H., Xu, C.X., Lim, H.T., et al. High dietary inorganic phosphate increases lung tumorigenesis and alters Akt signaling. Am J Respir Crit Care Med 179 (2009), 59–68.
130. 130 Go, A.S., Chertow, G.M., Fan, D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004), 1296–1305.
131. 131 Coe, L.M., Madathil, S.V., Casu, C., et al. FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis. J Biol Chem 289 (2014), 9795–9810.
132. 132 Brancaccio, D., Cozzolino, M., Gallieni, M., Hyperparathyroidism and anemia in uremic subjects: a combined therapeutic approach. J Am Soc Nephrol 15:Suppl 1 (2004), S21–S24.
133. 133 Rossaint, J., Oehmichen, J., Van Aken, H., et al. FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J Clin Invest 126 (2016), 962–974.
134. 134 Geara, A.S., Castellanos, M.R., Bassil, C., et al. Effects of parathyroid hormone on immune function. Clin Dev Immunol, 2010, 2010, 418695.
135. 135 Kir, S., Komaba, H., Garcia, A.P., et al. PTH/PTHrP receptor mediates cachexia in models of kidney failure and cancer. Cell Metab 23 (2016), 315–323.
136. 136 Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 113 (2009), S1–S130.
137. 137 Isakova, T., Gutierrez, O.M., Chang, Y., et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 20 (2009), 388–396.
138. 138 Lopes, A.A., Tong, L., Thumma, J., et al. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis 60 (2012), 90–101.
139. 139 Cannata-Andía, J.B., Fernández-Martín, J.L., Locatelli, F., et al. Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int 84 (2013), 998–1008.
140. 140 Shalhoub, V., Shatzen, E.M., Ward, S.C., et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 122 (2012), 2543–2553.
141. 141 Lavi-Moshayoff, V., Wasserman, G., Meir, T., et al. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 299 (2010), F882–F889.
142. 142 Block, G.A., Wheeler, D.C., Persky, M.S., et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 23 (2012), 1407–1415.
143. 143 Chue, C.D., Townend, J.N., Moody, W.E., et al. Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol 24 (2013), 842–852.
144. 144 Schiavi, S.C., Tang, W., Bracken, C., et al. Npt2b deletion attenuates hyperphosphatemia associated with CKD. J Am Soc Nephrol 23 (2012), 1691–1700.
145. 145 Isakova, T., Ix, J.H., Sprague, S.M., et al. Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD. J Am Soc Nephrol 26 (2015), 2328–2339.
146. 146 Bowling, C.B., Sharma, P., Fox, C.S., et al. Prevalence of reduced estimated glomerular filtration rate among the oldest old from 1988-1994 through 2005-2010. JAMA 310 (2013), 1284–1286.